Corporate Profile

Zura Bio is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. Currently, Zura Bio is developing three assets which have completed Phase 1/1b studies. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880), with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs.

Minimum 15 minutes delayed. Source:

News Releases

Upcoming Events

SEC Filings

An amendment to the SC 13G filing

SC 13G/A

Report of unscheduled material events or corporate event

8-K

A statement of beneficial ownership of common stock by certain persons

SC 13G